S100A8 and multiple sclerosis: Finally, a recent evidence on the use of small molecule inhibitors for S100A8 also suggested that blocking S100A8 activity exerts beneficial effects on disease activity in animal models of autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease (Pruenster et al., 2016).